Landiobloc (Landiolol Hydrochloride)

Landiolol Hydrochloride selectively blocks β1‑adrenergic receptors in the heart, reducing cyclic AMP production and calcium influx. This leads to decreased myocardial contractility and slower impulse generation, producing a rapid decline in heart rate and suppression of abnormal automaticity while preserving β2‑mediated functions in the lungs and vasculature.

The dosing regimen for Landiobloc is individualized. A qualified prescriber determines the initial infusion rate and any subsequent titration based on the patient’s clinical condition, response, and monitoring parameters. No fixed dose is provided here; clinicians follow local guidelines and product labeling.

Safety data for Landiolol Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any potential risk to the fetus or infant. Clinicians should assess risks carefully and consider alternative therapies when appropriate.

To request Landiobloc, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Both Landiobloc (landiolol) and esmolol are ultra‑short‑acting, cardioselective β1‑blockers used for rapid heart‑rate control. Landiolol has a slightly shorter half‑life and may provide more precise titration with fewer respiratory side effects, while esmolol is more widely available in some regions. Choice depends on clinical setting, physician preference, and local formulary considerations.

Landiobloc should be stored at room temperature, below 25 °C, in its original packaging. Protect the vials from light and moisture. Do not freeze. Before use, allow the solution to reach ambient temperature if it has been stored in a cooler, and inspect for particulate matter or discoloration.

Landiobloc is administered as an intravenous infusion. The initial rate is set by the prescriber and then titrated based on real‑time ECG and hemodynamic monitoring. Administration is typically performed in a monitored setting such as an intensive care unit, operating theatre, or emergency department.

The most serious adverse events include severe bronchospasm, high‑grade heart block, and profound hypotension that may lead to shock. Immediate recognition and supportive measures are essential. Continuous cardiac and respiratory monitoring during infusion helps detect these complications early.

Landiobloc is contraindicated in patients with known hypersensitivity to landiolol or any component of the formulation, severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and uncontrolled acute heart failure. Caution is also advised in patients with severe asthma or chronic obstructive pulmonary disease.